Stay updated on aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial
Sign up to get notified when there's something new on the aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial page.

Latest updates to the aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe page footer revision label was updated from v3.3.1 to v3.3.2. There are no changes to the study details or navigation.SummaryDifference0.1%

- Check21 days agoChange DetectedRevision updated from v3.2.0 to v3.3.1; no trial content or eligibility criteria appear to be affected.SummaryDifference0.1%

- Check29 days agoChange DetectedThe notice about government funding status and NIH operating status has been removed from the page. The core study details, eligibility criteria, and study plan remain unchanged.SummaryDifference0.4%

- Check43 days agoChange DetectedThe new screenshot appears to show cosmetic UI/layout adjustments and minor wording tweaks, with no alterations to core study data such as trial arms, eligibility criteria, endpoints, or enrollment numbers. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check72 days agoChange DetectedUpdated version to v3.2.0 and added a government-operating-status notice; removed the prior v3.1.0 tag.SummaryDifference4%

- Check79 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the aRCH With Cisplatin ± Pembrolizumab in HNSCC Clinical Trial page.